Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.